Kappa antagonist to prevent drug relapse: Does stage in addiction cycle matter?

Introduction: An upregulation of the kappa opioid receptor (KOR) system during drug preoccupation stage in addiction cycle will cause dysphoria among addicts which can lead to relapse. Therefore, KOR antagonism treatment might hold the key to prevent relapse. In this study, we aim to identify the ex...

Full description

Saved in:
Bibliographic Details
Published inInternational medical journal Malaysia Vol. 15; no. 1
Main Authors Ridzwan, Irna Elina, Zulkifli, Muhammad Harith, Wasli, Nur Syafinaz, Mohmad Faudzi, Syed Mohd Syahmi Syd
Format Journal Article
LanguageEnglish
Published 07.04.2020
Online AccessGet full text

Cover

Loading…
Abstract Introduction: An upregulation of the kappa opioid receptor (KOR) system during drug preoccupation stage in addiction cycle will cause dysphoria among addicts which can lead to relapse. Therefore, KOR antagonism treatment might hold the key to prevent relapse. In this study, we aim to identify the exact addiction’s stage in which KOR antagonist can be given. Methods: Using a conditioned place preference (CPP) model, adult male Swiss albino mice were divided into two major groups. The first group received treatment at the initial stage of morphine withdrawal (7.5 mg/kg, i.p) while the second group received treatment after complete abstinence was achieved. Each major groups were further divided into two treatment groups (n=8-12), either received a functional KOR antagonist (0.3 mg/kg buprenorphine/ 1 mg/kg naltrexone combination, i.p) or a selective KOR antagonist (10 mg/kg nor-BNI, i.p) prior to morphine priming (2.5 mg/kg, i.p). All data were analyzed using paired sample t-test. Results: The results showed that relapse was successfully attenuated in the groups that received KOR antagonists only after complete abstinence was successfully achieved (not significantly different from their baseline). However, the mice developed unusual sign of behavior sensitization (intermittent freezing, licking) when buprenorphine/naltrexone combination was given at initial stage of withdrawal. Conclusions: Our initial findings suggest that KOR antagonism might be beneficial only after the addicts achieved complete abstinence to prevent future druginduced relapse. Brain study should be conducted to explain the unusual behavior seen when the drug intervention is given at an earlier stage of withdrawal.
AbstractList Introduction: An upregulation of the kappa opioid receptor (KOR) system during drug preoccupation stage in addiction cycle will cause dysphoria among addicts which can lead to relapse. Therefore, KOR antagonism treatment might hold the key to prevent relapse. In this study, we aim to identify the exact addiction’s stage in which KOR antagonist can be given. Methods: Using a conditioned place preference (CPP) model, adult male Swiss albino mice were divided into two major groups. The first group received treatment at the initial stage of morphine withdrawal (7.5 mg/kg, i.p) while the second group received treatment after complete abstinence was achieved. Each major groups were further divided into two treatment groups (n=8-12), either received a functional KOR antagonist (0.3 mg/kg buprenorphine/ 1 mg/kg naltrexone combination, i.p) or a selective KOR antagonist (10 mg/kg nor-BNI, i.p) prior to morphine priming (2.5 mg/kg, i.p). All data were analyzed using paired sample t-test. Results: The results showed that relapse was successfully attenuated in the groups that received KOR antagonists only after complete abstinence was successfully achieved (not significantly different from their baseline). However, the mice developed unusual sign of behavior sensitization (intermittent freezing, licking) when buprenorphine/naltrexone combination was given at initial stage of withdrawal. Conclusions: Our initial findings suggest that KOR antagonism might be beneficial only after the addicts achieved complete abstinence to prevent future druginduced relapse. Brain study should be conducted to explain the unusual behavior seen when the drug intervention is given at an earlier stage of withdrawal.
Author Ridzwan, Irna Elina
Zulkifli, Muhammad Harith
Mohmad Faudzi, Syed Mohd Syahmi Syd
Wasli, Nur Syafinaz
Author_xml – sequence: 1
  givenname: Irna Elina
  surname: Ridzwan
  fullname: Ridzwan, Irna Elina
– sequence: 2
  givenname: Muhammad Harith
  surname: Zulkifli
  fullname: Zulkifli, Muhammad Harith
– sequence: 3
  givenname: Nur Syafinaz
  surname: Wasli
  fullname: Wasli, Nur Syafinaz
– sequence: 4
  givenname: Syed Mohd Syahmi Syd
  surname: Mohmad Faudzi
  fullname: Mohmad Faudzi, Syed Mohd Syahmi Syd
BookMark eNqdzjkLAjEQBeAgCp695fwB141Z16Ox8ECwsLEPw-4okd0kZKLgv_fAwtpp3hTvwdcVTessCTGUaaJkpvKxqa91cpdTIxOp5tOG6Mj5RI2yXMnmz98WA-Zr-rp8kWVq1hHHA3qPgDbixVnDEaIDH-hONkIZbhcIVKFnWsLGEQO_egTGApalKaJxFopHURHUGCOFVV-0zlgxDb7ZE-lue1rvR0VwzIHO2gdTY3homeqPXb_t-mPXb7v6Y_IEi1RQzA
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.31436/imjm.v15i1.1385
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1823-4631
ExternalDocumentID 10_31436_imjm_v15i1_1385
GroupedDBID 53G
5VS
AAYXX
ABDBF
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BCNDV
CITATION
DIK
EOJEC
ESX
GROUPED_DOAJ
GX1
KQ8
M~E
OBODZ
OK1
ID FETCH-crossref_primary_10_31436_imjm_v15i1_13853
ISSN 1823-4631
IngestDate Fri Aug 23 00:23:52 EDT 2024
IsPeerReviewed false
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-crossref_primary_10_31436_imjm_v15i1_13853
ParticipantIDs crossref_primary_10_31436_imjm_v15i1_1385
PublicationCentury 2000
PublicationDate 2020-04-07
PublicationDateYYYYMMDD 2020-04-07
PublicationDate_xml – month: 04
  year: 2020
  text: 2020-04-07
  day: 07
PublicationDecade 2020
PublicationTitle International medical journal Malaysia
PublicationYear 2020
SSID ssj0000694437
Score 4.3343244
Snippet Introduction: An upregulation of the kappa opioid receptor (KOR) system during drug preoccupation stage in addiction cycle will cause dysphoria among addicts...
SourceID crossref
SourceType Aggregation Database
Title Kappa antagonist to prevent drug relapse: Does stage in addiction cycle matter?
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dT9swFLUKSBMviDEQX0N-2MtUpTSfbXlBEwwxUJkETFS8RE4ct9lIGpWEqf01-6nca6cmRCDBXtLKca6s3CP7-vqeE0K-hLwbWI4wDeE5sEHpuZYRBIIZsHMwO6IrROAgUbh_4Z3-cs4G7qDR-FepWiryoBXOXuSV_I9XoQ38iizZd3hWG4UG-A_-hSt4GK5v8vE5yzLkVOHJEirgYiCZKU2mJp8UQ8lUyRT9_Hgc3WPiYChVQrCMSH0kPJyC0WYiZTZrVX7Ps4VJeaQz15roszsGPtbT-mXMZ39VOvUHdMCCsVTfvC3u_sRCUbH7xYglCeNIIIpznY6-Yffq_kUxaV5NmYDHZxoP4xE-ccIKPpOdrqYQKUMrx66jJIYfXs1gWG1Z-NKpTLpdyzYcr1wNohfa5jO1W0dkfQGwIfzDZESc_E5aD6Ybmy3TVt8Eeq61XVsDdWUi7ImkDR8t-NKCjxYWyJKFWvxIJx-YOouHtGFHCrPqAauzcGlkvzaMSuxTCWKuV8lKufug3xSUPpJGlK6RD_2yvuIT-SkRRZ8QRfMxLRFFEVG0RNQBRTxRiScap1TjiUo8UYWnw3XSPvl-fXRqzAfkZ0rdxH_tDdgbZDEdp9EmobYVhrZgXtcVHccJRU9EPe5yYUbtoGd79hb5-maz2-_ou0OWn_CzSxbzSRF9hpgwD_akWx4B6iZrAg
link.rule.ids 315,786,790,27946,27947
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Kappa+antagonist+to+prevent+drug+relapse%3A+Does+stage+in+addiction+cycle+matter%3F&rft.jtitle=International+medical+journal+Malaysia&rft.au=Ridzwan%2C+Irna+Elina&rft.au=Zulkifli%2C+Muhammad+Harith&rft.au=Wasli%2C+Nur+Syafinaz&rft.au=Mohmad+Faudzi%2C+Syed+Mohd+Syahmi+Syd&rft.date=2020-04-07&rft.issn=1823-4631&rft.eissn=1823-4631&rft.volume=15&rft.issue=1&rft_id=info:doi/10.31436%2Fimjm.v15i1.1385&rft.externalDBID=n%2Fa&rft.externalDocID=10_31436_imjm_v15i1_1385
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1823-4631&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1823-4631&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1823-4631&client=summon